Pharmaceuticals - BioReview (Page 2)

Pharmaceuticals

Roche's Fenebrutinib Emerges as Potential Breakthrough in Primary Progressive Multiple Sclerosis

In a landmark development that could transform treatment for one of neurology's most challenging conditions, Swiss pharmaceutical giant Roche has unveiled late-breaking Phase III data showing its investigational oral therapy fenebrutinib significantly slowed disability progression in people with primary progressive multiple sclerosis (PPMS). The results position fenebrutinib as

Biotechnology

Eli Lilly Makes Bold $2.4 Billion Bet on Revolutionary In Vivo CAR-T Technology with Orna Therapeutics Acquisition

Eli Lilly's $2.4 billion acquisition of Orna Therapeutics marks a transformative entry into in vivo CAR-T therapy, leveraging revolutionary circular RNA technology to democratize cell therapy for autoimmune diseases.

Biotechnology

REGENXBIO Faces Critical Setback as FDA Halts Gene Therapy Trials Following Pediatric Brain Tumor Discovery

REGENXBIO announced that the FDA has placed clinical holds on RGX-111 and RGX-121 following the discovery of a brain tumor in a pediatric patient treated with gene therapy, raising critical questions about AAV vector safety.

Biotechnology

Affinia Therapeutics Breaks New Ground: FDA Clears First Gene Therapy Trial for Rare Heart Disease

In a significant regulatory milestone that could transform treatment for one of cardiology's most challenging genetic conditions, Affinia Therapeutics announced on February 5, 2026, that the FDA has cleared its Investigational New Drug (IND) application for AFTX-201, marking a pivotal moment in the development of gene therapies for

Pharmaceuticals

Hanmi Pharmaceutical Achieves FDA Breakthrough Designation for Revolutionary Rare Disease Treatment

In a significant regulatory milestone that could transform treatment for one of medicine's most challenging rare diseases, South Korea-based Hanmi Pharmaceutical announced on February 5, 2026, that the FDA has granted Breakthrough Therapy Designation to efpeglucagon (HM15136) for treating congenital hyperinsulinism (CHI). This designation positions the investigational therapy

Pharmaceuticals

After BMS’s $850M Bet on Tumor-Activated Immunotherapy, Investors Are Asking: Who’s Next?

Bristol Myers Squibb’s $850M Janux deal highlights growing pharma interest in tumor-activated immunotherapy. Purple Biotech is an under-the-radar player advancing a conditionally activated, multi-mechanism approach aligned with this emerging shift in solid tumor treatment.

Biotechnology

Micoy Therapeutics Achieves FDA Breakthrough Designation for Revolutionary Point-of-Care Test Targeting Folate Deficiency

In a significant regulatory milestone that could transform diagnostic testing for a critical nutritional deficiency, Brooklyn-based Micoy Therapeutics announced on January 12, 2026, that the FDA has granted Breakthrough Device Designation to its NeuroLume™ Test. This innovative point-of-care diagnostic represents the first FDA-recognized test specifically designed to detect folate receptor

Biotechnology

Biogen Achieves Regulatory Milestone as FDA Grants Breakthrough Status to First-in-Class Lupus Therapy

In a significant regulatory achievement that could transform treatment for millions of Americans living with a debilitating autoimmune skin condition, Biogen announced on January 28, 2026, that the FDA has granted Breakthrough Therapy Designation to litifilimab (BIIB059) for treating cutaneous lupus erythematosus (CLE). This milestone positions the investigational therapy as

Biotechnology

Adolore BioTherapeutics Breaks New Ground: FDA Grants Orphan Drug Status for Revolutionary Gene Therapy Targeting Rare Pain Disorder

Florida-based Adolore BioTherapeutics announced that the FDA has granted Orphan Drug Designation to its innovative rdHSV-CA8* gene therapy for treating erythromelalgia, positioning the company at the forefront of a revolutionary approach to chronic pain management.

Pharmaceuticals

Pharming Group Faces Regulatory Setback as FDA Issues Complete Response Letter for Pediatric APDS Treatment

Pharming Group announced that the FDA issued a Complete Response Letter for its supplemental application to expand Joenja treatment to children aged 4-11 with APDS, citing concerns about dosing precision and manufacturing quality.

Pharmaceuticals

Tenpoint Therapeutics Achieves Historic FDA Approval for YUVEZZI: First Dual-Agent Eye Drop Transforms Presbyopia Treatment

Tenpoint Therapeutics announces FDA approval of YUVEZZI, the first dual-agent prescription eye drop for presbyopia, marking a historic regulatory milestone in treating age-related vision loss affecting 128 million Americans.

Pharmaceuticals

Serina Therapeutics Overcomes Regulatory Hurdle as FDA Clears Path for Revolutionary Parkinson's Treatment

Serina Therapeutics announced FDA clearance of its IND application for SER-252, an innovative apomorphine therapy for advanced Parkinson's disease, marking a significant regulatory victory after successfully addressing previous clinical hold concerns.